The Postgraduate Year Two Oncology Pharmacy Residency at Seattle Children’s is a one-year ASHP accredited training program that provides training in the field of oncology with a focus on pediatrics. Experience is gained in general hematology / oncology, stem cell transplantation and ambulatory care. Opportunities to explore additional areas of interest are available through electives both on and off site. Seattle Children’s has 207 licensed beds with 48 Cancer Care Unit beds, over 15,500 annual inpatient admissions, and more than 330,000 ambulatory visits in 2021. Our comprehensive, multidisciplinary team of pediatric cancer experts treats more than 250 newly diagnosed patients with cancer every year and provides follow-up care to more than 12,700 children and adolescents.
Program Purpose
PGY2 pharmacy residency programs build on Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.
Practice Areas
Orientation/Training
3-4 weeks
Hematology/Oncology Inpatient
split between Solid and Liquid tumor teams throughout the year
18 weeks
Hematopoietic Stem Cell Transplantation Inpatient
12 weeks
(6 weeks/rotation)
Ambulatory Care
Split between oncology and BMT
6-8 weeks
Drug Information
Longitudinal
Project Time
4 weeks divided
Investigation Drug Services- Hematology Oncology Specific
Seattle Children’s has 371 licensed beds with 48 Cancer Care Unit beds, over 15,500 annual inpatient admissions, and more than 330,000 ambulatory visits in 2015. Our comprehensive, multidisciplinary team of pediatric cancer experts treats more than 250 newly diagnosed patients with cancer every year and provides follow-up care to more than 12,700 children and adolescents.